What Happened?
Boulder, CO-based Chris Morl as Chief Business Officer
About the Company
Miragen Therapeutics, Inc., is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. From its founding, miRagen has developed ongoing, collaborative relationships with academic institutions that give the company unique access to the most promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of miRNA-targeting therapeutics.
About the Person
Mr. Christopher J. Morl, also known as Chris, M.B.A., B.Sc. (Hons) has been Chief Business Officer of Miragen Therapeutics, Inc. since June 11, 2013. Mr. Morl has more than 25 year of pharmaceutical and biotechnology industry experience. Prior to joining miRagen, Mr. Morl worked as a consultant advising pre-clinical and clinical stage biotech companies on corporate strategy, business development and financing. Mr. Morl served as Chief Operating Officer at Ambit Biosciences Corporation since 2010 and served as its Chief Business Officer sine joining in 2009
Info Source
News
Short Profile